Suggestions
Laurent Humeau
Chief Scientific Officer and Executive Vice President of Research and Development
Laurent Humeau is a Board Member at Geneos Therapeutics with extensive experience in the biotechnology industry.1 He is currently based in San Diego and has over 500 connections on LinkedIn.1
Professional Background
Laurent Humeau has a strong educational foundation, having studied at Université Denis Diderot (Paris VII).1 This academic background likely contributed to his expertise in the field of therapeutics and biotechnology.
Career at Geneos Therapeutics
At Geneos Therapeutics, Laurent Humeau plays a significant role as a Board Member. The company appears to be focused on developing innovative therapeutic solutions, given Humeau's background and the nature of his position.1
Industry Involvement
Humeau seems to be actively engaged in the biotechnology community. He has shown appreciation for other professionals in the field, such as Boro Dropulić, whom he described as "one of the unsung heroes who has dedicated his life in making patients' lives better".2 This indicates that Humeau values collaboration and recognizes the contributions of others in advancing medical science.
LinkedIn Presence
Laurent Humeau's LinkedIn profile can be found under the username 02041967.1 His profile likely provides more detailed information about his professional experiences, achievements, and areas of expertise within the biotechnology and therapeutics sectors.
Highlights
As I see more and more posts mentioning Profs. Carl June and Bruce Levine for their outstanding achievements in the CAR-T field, and please do not get me wrong, they truly deserve it, I felt it was important to give a "shout out" to Dr. Boro Dropulic as well for his overall contribution in this therapeutic achievement (https://lnkd.in/gVja8_as). Boro is one of the unsung heros who has dedicated his life in making patients' lives better. Without Boro and his seminal work on the clinical translation of the lentiviral vector platform, patients would not have benefited of the CAR-T successes as we now know it. It has been a bumpy road to get to 2011 NEJM landmark publication, and Boro was behing it with Lentigen. The first subjects dosed with LVV modified T cells were produced by Boro's first company, VIRxSYS. Granted it took a village to get there, and the convergence of several great minds to make CAR-Ts a success, but I simply wanted to acknowledged Boro for having this vision of leveraring HIV as a genetic payload delivery system and make it a reality so many years before anyone else, and starting by convincing VCs to fund VIRxSYS in the very late 90s when they were more interested in investing in startups working on gas pumps delivering additives for engine performance. For full disclosure I have no stake in Boro's current endeavors, and yes I worked with him in the early 2000s. Again I just wanted to remind us all how outstanding Boro is. Please visit his current efforts, including "Caring Cross", his non-profit aiming to deliver advanced/cutting edge medicine to underserved community in the world. The man cares, and he is showing it to us every day...
I’m happy to share that I’m starting a new position as Board Member at Geneos Therapeutics!
